ARTIFACTS IN THE ANALYSIS OF THIORIDAZINE AND OTHER NEUROLEPTICS

被引:19
作者
EAP, CB
KOEB, L
BAUMANN, P
机构
[1] Unité de biochimie et psychopharmacologie clinique, Département Universitaire de Psychiatrie Adulte (DUPA), CH-1008 Prilly-Lausanne, Site de Cery
关键词
THIORIDAZINE; BUTYROPHENONES; PHENOTHIAZINES; THIOXANTHENES; NEUROLEPTICS; THERAPEUTIC DRUG MONITORING; LIGHT; ARTIFACTS;
D O I
10.1016/0731-7085(93)80157-V
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Although the sensitivity to light of thioridazine and its metabolites has been described, the problem does not seem to be widely acknowledged. Indeed, a survey of the literature shows that assays of these compounds under light-protected conditions have been performed only in a few of the numerous analytical studies on this drug. In the present study, thioridazine, its metabolites, and 18 other neuroleptics were tested for their sensitivity to light under conditions used for their analysis. The results show that light significantly affects the analysis of thioridazine and its metabolites. It readily causes the racemization of the isomeric pairs of thioridazine 5-sulphoxide and greatly decreases the concentration of thioridazine. This sensitivity to light varied with the medium used (most sensitive in acidic media) and also with the molecule (in order of decreasing sensitivity: thioridazine > mesoridazine > sulforidazine). Degradation in neutral or basic media was slow, with the exception of mesoridazine in a neutral medium. Twelve other phenothiazines tested, as well as chlorprotixene, a thioxanthene drug, were found to be sensitive to light in acidic media, whereas flupenthixol and zuclopenthixol (two thioxanthenes), clozapine, fluperlapine, and haloperidol (a butyrophenone) did not seem to be affected. In addition to being sensitive to light, some compounds may be readily oxidized by peroxide-containing solvents.
引用
收藏
页码:451 / 457
页数:7
相关论文
共 36 条
[11]   THIORIDAZINE 5-SULFOXIDE DIASTEREOISOMERS IN SERUM AND URINE FROM RATS AND MAN AFTER CHRONIC THIORIDAZINE ADMINISTRATION [J].
HALE, PW ;
POKLIS, A .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1985, 9 (05) :197-201
[12]  
JUENGE EC, 1983, J PHARM SCI, V772, P617
[13]   SIMULTANEOUS DETERMINATION OF THIORIDAZINE AND ITS OXIDIZED AND N-DEMETHYLATED METABOLITES USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ON RADIALLY COMPRESSED SILICA [J].
KILTS, CD ;
PATRICK, KS ;
BREESE, GR ;
MAILMAN, RB .
JOURNAL OF CHROMATOGRAPHY, 1982, 231 (02) :377-391
[14]  
LEWIS MH, 1986, PSYCHOPHARMACOL BULL, V22, P1040
[15]  
MARTENSSON E, 1975, CURR THER RES CLIN E, V18, P687
[16]   REVERSE-PHASE HPLC DETERMINATION OF THIORIDAZINE AND MESORIDAZINE IN WHOLE-BLOOD [J].
MCCUTCHEON, JR .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1979, 3 (03) :105-107
[17]  
MEYER JW, 1990, EUR J CLIN PHARMACOL, V3997, P6131
[18]   PHOTOSENSITIZATION BY DRUGS - PHOTOLYSIS OF SOME CHLORINE-CONTAINING DRUGS [J].
MOORE, DE ;
TAMAT, SR .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1980, 32 (03) :172-177
[19]   MEASUREMENT OF THIORIDAZINE IN BLOOD AND URINE [J].
NG, CH ;
CRAMMER, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 4 (02) :173-183
[20]   CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS MAIN METABOLITES IN PSYCHIATRIC-PATIENTS [J].
NYBERG, G ;
AXELSSON, R ;
MARTENSSON, E .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 19 (02) :139-148